Stocklytics Platform
Asset logo for symbol NRIX
Nurix Therapeutics
NRIX64
$19.57arrow_drop_down2.22%-$0.44
Asset logo for symbol NRIX
NRIX64

$19.57

arrow_drop_down2.22%

Performance History

Chart placeholder
Key Stats
Open$19.77
Prev. Close$19.98
EPS-2.90
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range19.11
19.93
52 Week Range4.22
29.45
Ratios
EPS-2.90

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Nurix Therapeutics (NRIX)

Nurix Therapeutics, Inc. (NRIX) is a biopharmaceutical company specializing in the discovery and development of small molecule targeted protein modulation therapies. The company's proprietary drug discovery platform, DELigase, enables the identification of novel compounds that can modulate the ubiquitin-proteasome system, a key regulatory network within cells. By modulating the activity of specific proteins, Nurix aims to develop therapies for a wide range of diseases, including cancer, immune disorders, and neurodegenerative diseases.
In recent news, Nurix Therapeutics announced positive results from a Phase 1 clinical trial for NUR-202, its lead drug candidate for the treatment of solid tumors. The trial showed encouraging signs of safety and efficacy, with several patients experiencing tumor regression and disease stabilization. These results have generated significant excitement among investors and healthcare professionals, positioning Nurix as a promising player in the field of targeted protein modulation therapies.
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Arthur T. Sands M.D., Ph.D.
Headquarters
San Francisco
Employees
297
Exchange
NASDAQ
add Nurix Therapeutics to watchlist

Keep an eye on Nurix Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Nurix Therapeutics's (NRIX) price per share?

The current price per share for Nurix Therapeutics (NRIX) is $19.57. The stock has seen a price change of -$0.45 recently, indicating a -2.23% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Nurix Therapeutics (NRIX)?

For Nurix Therapeutics (NRIX), the 52-week high is $29.46, which is 50.53% from the current price. The 52-week low is $4.22, the current price is 363.74% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Nurix Therapeutics (NRIX) a growth stock?

Nurix Therapeutics (NRIX) has shown an average price growth of -5.34% over the past three years. It has received a score of 66 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Nurix Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Nurix Therapeutics (NRIX) stock price performance year to date (YTD)?

As of the latest data, Nurix Therapeutics (NRIX) has a year-to-date price change of 91.49%. Over the past month, the stock has experienced a price change of -10.31%. Over the last three months, the change has been -16.83%. Over the past six months, the figure is -5.91%.
help

Is Nurix Therapeutics (NRIX) a profitable company?

Nurix Therapeutics (NRIX) has a net income of -$143.95M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -433.83% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $76.99M, with a revenue growth rate of 99.31%, providing insight into the company's sales performance and growth. Operating income is noted at -$155.06M. Furthermore, the EBITDA is -$186.4M.
help

What is the market capitalization of Nurix Therapeutics (NRIX)?

Nurix Therapeutics (NRIX) has a market capitalization of $1.38B. The average daily trading volume is 19.46, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level